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Abstract: The recently emerged Zika virus (ZIKV) spread to the Americas, causing a spectrum of 
congenital diseases including microcephaly in newborn and Guillain-Barré syndrome (GBS) in 
adults. The unprecedented nature of the epidemic and serious diseases associated with the viral 
infections prompted the global research community to understand the immunopathogenic 
mechanisms of the virus and rapidly develop safe and efficacious vaccines. This has led to a number 
of ZIKV vaccine candidates that have shown significant promise in human clinical trials. These 
candidates include nucleic acid vaccines, inactivated vaccines, viral-vectored vaccines, and 
attenuated vaccines. Additionally, a number of vaccine candidates have been shown to protect 
animals in preclinical studies. However, as the epidemic has waned in the last three years, further 
development of the most promising vaccine candidates faces challenges in clinical efficacy trials, 
which is needed before a vaccine is brought to licensure. It is important that a coalition of 
government funding agencies and private sector companies is established to move forward with a 
safe and effective vaccine ready for deployment when the next ZIKV epidemic occurs. 
Keywords: Zika virus; vaccine platforms and vaccine candidates; correlates of protection; 
immunoinformatics; ADE 
 
1. Zika Virus: History and Biology 
Zika virus (ZIKV), a mosquito-borne flavivirus, was isolated in 1947 from the blood sample of a 
sentinel rhesus monkey in the Zika forest of Uganda [1]. Although the first case of human infection 
by ZIKV was described in Nigeria in the early 1950s, only sporadic outbreaks of infections were 
reported in Africa and Asia over the next few decades. The virus emerged in 200,7 causing an 
outbreak in the Yap Island of Federated States of Micronesia, with the majority of symptomatic 
patients exhibiting fever, rash, and arthritis/arthralgia [2]. A larger outbreak of the virus followed in 
French Polynesia and other Pacific Islands in late 2013, where, in addition to the above-described 
symptoms, conjunctivitis was also noted [3,4]. The virus was subsequently detected for the first time 
in Brazil in 2015, causing infections in epidemic proportions [5], although epidemiological studies 
through viral genome sequence analysis suggest that the virus may have been circulating in the 
northeastern part of the country as early as late 2013 [6]. The virus rapidly spread to many countries 
in the Americas and other parts of the world [7,8]. The incidences of ZIKV infections in the Americas 
peaked in early 2016 with the cumulative number of documented and suspected cases exceeding 1 
million. However, the number of incidences in the Americas and the world has waned significantly 
after 2017.  
The ZIKV epidemic in Brazil, as well as other countries, was linked to devastating congenital 
Zika syndrome (CZS) including microcephaly, congenital malformation, and fetal demise, 
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particularly when women are infected with the virus during the first trimester of pregnancy [9–15]. 
ZIKV infections were also found to be associated with Guillain–Barré syndrome (GBS) in adults, an 
auto-immune disease of the peripheral nerves that can result in muscle weakness and paralysis [16–
19]. Since ZIKV infections prior to 2013 were mostly associated with mild disease symptoms, these 
unexpected severe diseases such as GBS and CZS associated with the virus infections led the World 
Health Organization (WHO) to declare ZIKV as a Public Health Emergency of International Concern 
[20]. This prompted the global health and research community to not only understand the biology 
and pathogenesis of the virus but also devise strategies for prevention and control measures, 
including the development of safe and efficacious vaccines and antivirals against ZIKV.  
The primary mode of ZIKV transmission is through mosquito bite; however, the virus has been 
shown to be transmitted sexually [21–23], through the maternal–fetal route [24–26] and through 
blood transfusion [27,28]. The incubation period is estimated to range from 3 to 14 days [29]. The 
majority (80% or more) of individuals infected with ZIKV do not show any symptoms while some 
develop mild symptoms including fever, rash, conjunctivitis, headache, malaise, muscle, and joint 
pain lasting for 2 to 7 days, that self-resolve with time. However, in a very small number of cases, 
infections can lead severe diseases, such as GBS in adults and CZS in pregnant women, with a variety 
of pathological abnormalities of the fetus such as craniofacial, musculoskeletal, ocular, pulmonary, 
in addition to microcephaly [14,30]. Recent studies have revealed that ZIKV infection of male mice 
can result in virus persistence and testis damage leading to reduced fertility [31,32]. In addition, case 
studies in Brazil have also suggested that ZIKV infection may be responsible for reduced fertility in 
men [33]. Zika virus infection also results in conjunctivitis and causes persistent chorioretinal lesions 
with uveitis in humans and mice models [34,35]. Unlike the previous ZIKV outbreaks, it is still not 
fully understood as to which genomic changes may have resulted in the high pathogenicity of the 
virus in recent outbreaks with such a wide spectrum of diseases.  
Serologic and genome analyses suggest the existence of only one single serotype with three 
distinct genetic lineages: East African (that includes the first isolate from Uganda, MR766), West 
African, and Asian, including the first isolate from Asia (P6-740) and all contemporary strains from 
Asia, Oceania, and the Americas [36,37]. Like most other mosquito-transmitted flaviviruses [such as 
dengue virus (DENV), West Nile virus (WNV), Japanese encephalitis virus (JEV), yellow fever virus 
(YFV)], ZIKV is enveloped and contains a positive-sense, single-stranded RNA genome of ~11 
kilobases. The genome encodes a single ORF, which is translated to produce a large polyprotein that 
is processed by viral and cellular proteases leading to three amino–terminal structural proteins 
(capsid, C; pre-membrane, prM; and envelope, E) and seven carboxy–terminal non-structural (NS) 
proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). While the structural proteins are primarily 
involved in virion assembly, attachment, and entry into host cells, the NS proteins participate in viral 
genome replication, virion assembly, polyprotein processing, and evasion of host antiviral responses. 
The virions are assembled in the endoplasmic reticulum as immature virions containing 60 copies of 
the prM-E heterotrimers. During transport through the secretory pathway, prM molecules are 
cleaved by the host furin-like proteases in the trans-Golgi region into pr and M polypeptides, but 
following the release of the virions from the host cell, the pr peptide is removed, and M-E are 
rearranged into 90 copies of heterodimers generating thermally stable infectious virions [38–40]. Like 
most other flavivirus E proteins, the ZIKV E protein elicits neutralizing antibody responses [41], and 
therefore has been the major target for development of vaccines. Other viral proteins such as prM 
and NS1 proteins have also been used as targets for vaccine development. 
2. Immune Reponses to Zika Virus Infection, Vaccination, and Correlates of Protection 
Zika virus induces both innate and adaptive immune responses by the host. It is well established 
that type I interferon (IFN) induction and signaling are able to restrict ZIKV infection in cell culture 
and in mouse models [42–44]. On the other hand, ZIKV inhibits IFN induction and signaling by a 
variety of mechanisms [45]. All of the viral NS proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and 
NS5) appear to play role(s) in the inhibition of type I IFN production and IFN-stimulated gene (ISG) 
induction [45]. The observations that ZIKV replicates well and causes disease in animals lacking 
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components of innate immune signaling pathways such as IFNα/β receptor [44], STAT2 [46] suggest 
that innate immune response to ZIKV infection is the first line of defense against the pathogen.  
The adaptive immune responses (humoral and cellular) to ZIKV are protective. The humoral 
responses generating virus-specific neutralizing antibodies predominantly directed against the viral 
E protein appear to be most important for protection [47–49]. Overall, these antibodies fall into 
several classes based on their ability to recognize different regions or structures of the E protein. They 
either recognize a quaternary epitope on the E protein dimer–dimer interface and protect the vertical 
transmission of ZIKV in mice model [47,50]; recognize residues in the lateral ridge epitope of domain 
III (DIII) and block ZIKV infection at a post-attachment stage [51]; or recognize a quaternary epitope 
spanning all three domains of the E dimer, protecting mice from lethal virus challenge and vertical 
transmission [52,53]. This last class of antibodies also cross-reacts with DENV and enhance its 
replication [48] with implications for the antibody-dependent enhancement (ADE) of infection and 
disease. Therefore, the design of an ideal vaccine that induces antibody responses should take ADE 
into consideration.  
Although humoral responses to ZIKV infections have been well characterized and documented, 
cellular immune responses are less well studied. ZIKV-specific CD4+ and CD8+ T cell responses 
directed at the C, E, and the NS1 proteins have been demonstrated in virus-infected humans, non-
human primates (NHPs), and mice [48,54–58]. A protective role for CD8+ T cells against ZIKV was 
demonstrated by showing that (i) CD8-/- mice display higher virus replication and increased 
mortality [59], and (ii) adoptive transfer of ZIKV-immune CD8+ T cells reduces viral burden whereas 
their depletion leads to increased viral burden [60]. Although neutralizing antibodies and CD8+ T 
cells are primarily responsible for the protective adaptive immune response to ZIKV, the role of CD4+ 
T cells is less clear. It appears that CD4+ T cells with Th1 phenotype and IFNγ signaling are required 
for neutralizing antibody response [58,61–63] and thus may play an indirect role in protection from 
ZIKV. An optimal vaccine candidate, therefore, should have the ability to induce both CD4+ and 
CD8+ T cell responses in addition to strong humoral responses.  
Early studies demonstrating that infection of rhesus macaques with ZIKV could induce adaptive 
immune responses including neutralizing antibody production and protect the animals from 
challenge with the homologous virus suggest that adaptive immune responses are protective [56]. 
However, defining the immune correlates that are associated with protection from infection and/or 
disease is challenging, since (i) different vaccine candidates induce different degrees of B and T cell 
responses, (ii) the immune correlates of protection will be different for different human target 
populations such as children, adults, and the fetus, in addition to individuals with pre-existing 
flavivirus immunity, with neurologic disorders, autoimmune diseases, immunosuppression, women 
of reproductive age, pregnant women, etc., (iii) correlates of protection in humans would likely be 
different from those obtained from various animal models, and (iv) human vaccine clinical trials 
would face considerable ethical issues, particularly with inclusion of pregnant women, given the as-
yet fully uncharacterized spectrum of congenital diseases that may be associated with the virus 
infection.  
Despite these challenges and shortcomings, multiple ZIKV vaccine candidates under various 
platforms have been developed over the last four years to determine if vaccines can confer protection 
against the virus challenge in animal models [64–67]. These include inactivated vaccines, live 
attenuated vaccines, and subunit vaccines. Many of these vaccine candidates induce high levels of 
neutralizing antibodies as well as cellular immune responses that confer protection in mice and NHP 
models. The general consensus from these studies is that protective efficacy of a vaccine is strongly 
linked to neutralizing antibody response, although in one study, protection was found to be 
independent of neutralizing antibodies in a phase I clinical trial [68], where the adoptive transfer of 
sera containing non-neutralizing, ZIKV-binding antibodies from several DNA-vaccinated humans 
was shown to protect mice by an as-yet undetermined mechanism. The serum antibody titers 
required for the protection of mice and NHPs in challenge studies have been estimated to be 
approximately 100 to 1000 [69–71]. Although the protective efficacy of many of the vaccine candidates 
has been tested in mice and NHPs, the serum titers of the neutralizing antibodies required for 
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protection in humans will likely be different and must be determined through clinical trials. Using 
purified formalin-inactivated Zika virus vaccine (ZPIV) or DNA vaccine in human clinical trials, 
antibody titers of ≥10 and as high as over 100 have been generated [72,73]. Based on previously 
licensed flavivirus vaccines such as those for JEV, YFV, etc., neutralization titers of 10 have been 
considered as surrogates of protection [74]. Therefore, it is conceivable that the antibody titers of 
greater than 10 might be adequate for ZIKV protection in humans, although the precise titers for 
complete protection needs to be determined from further clinical studies. Furthermore, data from 
randomized placebo-controlled clinical trials in volunteers from ZIKV and other flavivirus endemic 
areas are needed before any vaccine for ZIKV is deployed. Additional considerations must also be 
given to establish correlates of protection in pregnant women and the fetus from congenital 
malformation.  
3. Antibody-Dependent Enhancement (ADE) of Infection and Disease: Implications for ZIKV 
Vaccine Design  
ZIKV, DENV, as well as other flaviviruses, share considerable genetic and structural similarities 
[75] and therefore generate cross-reactive antibodies [76,77] that can be poorly neutralizing but can 
potentially cause antibody-dependent enhancement (ADE) of virus infection and disease. It has been 
found that cross-reactive DENV antibodies that are poorly neutralizing or neutralizing antibodies at 
subneutralizing concentrations can promote virus entry into cells bearing FcγRs, enhance virus 
replication, and exacerbate the virus associated diseases in humans [78–80]. Epidemiological studies 
suggest that previous infection with a DENV serotype may predispose an individual to more severe 
disease such as hemorrhagic fever due to secondary infection with an unrelated serotype of the virus 
[81]. The secondary infection in the presence of these antibodies enhances virus uptake and 
replication, which may then result in a cytokine storm through the activation of memory T cell 
responses, leading to the enhancement of the disease. Since ZIKV infections occurred in many places 
where DENV is endemic, it was postulated that the presence of previous DENV antibodies may have 
exacerbated ZIKV infections and related diseases. In fact, studies show that human antibody 
responses following DENV or other flavivirus infections are highly cross-reactive to ZIKV [82] and 
that such antibodies mediate the ADE of ZIKV infection in cell culture and mice, although this has 
not been seen in NHPs [83–85]. Likewise, cross-reactive ZIKV antibodies have been shown to mediate 
ADE of DENV [48,86]. Whether pre-existing antibodies to DENV mediate the ADE of ZIKV in 
humans is not clear at this time, but a preliminary epidemiological study has found no evidence for 
this [87]. Interestingly, a recent study [88] demonstrated that the administration of a ZIKV inactivated 
vaccine in DENV-experienced humans resulted in potent cross-neutralizing antibodies to both ZIKV 
and DENV, suggesting that ZIKV vaccination in DENV and other flavivirus-endemic areas might be 
beneficial. 
Examination of human monoclonal antibodies from flavivirus-infected individuals suggests that 
the fusion loop epitope (FLE) within the E protein domain II (EDII) is an immunodominant epitope 
with broad cross-reactivity to flaviviruses [76–78]. The FLE-specific antibodies directed against 
DENV- and ZIKV-infected individuals have been shown to induce the ADE of ZIKV in vitro and 
mice model [83,89]. Another immunodominant epitope within the prM has also been identified that 
generates cross-reactive antibodies and induces ADE [76–78]. Therefore, ZIKV vaccine design 
approaches should consider abrogating ADE. This could be achieved by using E protein regions that 
lack FLE or having immunogens where the exposure of FLE to the host’s immune system is blocked 
or minimized. Other vaccine candidates that circumvent the risk of ADE are also being developed. 
Notable among those is the NS1 protein, which has been shown to induce protective antibody 
responses as well as T cell responses [63,90–92]. Although it is typically not considered an antigen for 
vaccine development, flavivirus NS1 is immunogenic, expressed intracellularly and on the surface of 
infected cells as well as in secreted form, and is shown to induce protective immune responses [93–
95]. 
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4. Zika Virus Vaccine Development: Current Status 
With the explosion of ZIKV cases in the Americas in 2016 and established association with 
neurological and congenital diseases, intense efforts were made towards the development of a 
number of vaccine candidates that could be tested in preclinical and clinical trials. The WHO ZIKV 
vaccine development roadmap provided a framework of two scenarios for such vaccine use: outbreak 
use, and endemic use [96]. The former scenario entails the mass vaccination of susceptible population 
including pregnant women and women of child-bearing age during an ongoing epidemic while the 
latter involves the broad vaccination of the general population during inter-epidemic times. The 
accelerated development of several ZIKV vaccine candidates was largely due to past experience with 
the development of several successful flavivirus vaccines and more detailed knowledge of the 
biology and pathogenesis of ZIKV and development of animal models [97]. Several different ZIKV 
vaccine candidates under different platforms (Figure 1) have now been developed and tested in 
preclinical and clinical trials. These include: nucleic acid vaccines (DNA and RNA vaccines), 
inactivated whole virus vaccines, live attenuated vaccines, viral vectored vaccines, protein antigen 
vaccines in the form of purified proteins from expression systems, or virus-like particles. Several of 
these candidates are in various stages of preclinical studies or in human clinical trials. Although the 
development of peptide vaccines based on immunoinformatics approaches has been proposed, such 
vaccines have not come to a stage for preclinical trials yet. 
 
Figure 1. Schematic of various ZIKV vaccine platforms. Three major platforms: inactivated, subunit, 
and live attenuated/viral-vectored vaccines have been used to generate a number of vaccine 
candidates for preclinical and clinical testing. A variety of approaches and immunogens as shown 
were used. Immunoinformatics-based peptide vaccines have not been generated/tested (???). MV, 
measles virus; Ad, adenovirus; VSV, vesicular stomatitis virus; VV, vaccinia virus. 
Each of these vaccine platforms induce humoral and/or cell-mediated immune responses to 
varying degrees. The inactivated vaccines are usually safe and could be administered to most target 
populations including pregnant women as well as women of child-bearing ages. However, multiple 
doses and use of adjuvants may be needed for the induction of more robust and long-lasting 
protection. ADE is also a concern with these vaccines. Among subunit vaccines, nucleic acid-based 
vaccines using prM-E genes generate VLPs similar to virus particles that are released from cells and 
therefore these, along with VLP-based vaccines, present the viral antigens to the host immune system, 
similar to the infectious virus. Additionally, some subunit vaccines based on NS1 or EDIII are 
designed to avoid ADE. The subunit vaccines are generally considered as safe, depending the nature 
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of the adjuvants, for use in all target population, including pregnant women. Live attenuated and/or 
several of the viral-vectored vaccines also generate infectious particles and/or VLPs and have similar 
advantages to some of the subunit vaccines. However, these vaccines, along with live attenuated 
ZIKV vaccines, could present problems with potential reversion to virulent forms, could induce toxic 
inflammatory responses, or could be less effective due to pre-existing immunity to the vectored virus. 
4.1. Nucleic Acid Vaccines  
Nucleic acid vaccines have been under development as potential vaccine candidates for over 25 
years as they can be generated fairly quickly from the genetic sequence of the desired antigen or 
protein. Additionally, these vaccine candidates bypass the cumbersome process of expressing the 
antigen or protein and having it purified prior to use. Therefore, both DNA and mRNA vaccines have 
generated significant interest as vaccine candidates in recent years [98,99]. However, the potential 
disadvantages of nucleic acid vaccines include relative instability, delivery, integration into the host 
genome, toxicity, and immunostimulatory and inflammatory responses by the host. Notwithstanding 
these limitations, nucleic acid vaccines have become the choice of future vaccine platforms by 
mitigating the limitations and increasing the potency of these platforms [100]. Several DNA and RNA 
vaccines candidates for ZIKV have now been developed and are in various stages of human clinical 
trials. 
4.1.1. DNA Vaccines 
The proof-of-concept for use of a DNA vaccine against ZIKV was first developed using the 
coding sequences of the viral prM-E regions in plasmids and examining immune responses in mice 
[101] and NHPs [70]. In these studies, the plasmid constructs generated prM-E or M-E (with deletion 
of pr region) proteins. The induction of high levels of ZIKV-specific neutralizing antibodies was 
observed when the plasmid DNA was injected into mice or NHPs [70,101]. In a similar approach, two 
other DNA constructs were generated based on prM-E sequences as well [69]. JEV signal sequences 
(SS) were inserted in the place of ZIKV prM SS at the amino-terminal region in the plasmid VRC5283 
whereas in the plasmid VRC5288, sequences encoding the carboxy-terminal 98 amino acids of E were 
replaced with the corresponding sequences from JEV in addition to the JEV SS at the amino-terminus. 
These constructs directed the expression of prM-E and secretion of subviral particles (SVPs) with 
VRC5288 directing significantly higher levels of secretion of SVPs into culture supernatants. Rhesus 
macaques vaccinated with these DNA constructs elicited a robust neutralizing response that 
protected the animals from ZIKV challenge. The VRC5283 vaccine candidate exhibited better 
protection, likely due to superior immunogenicity of the encoded protein. Additionally, the VRC5283 
vaccine was also shown recently to protect immunocompromised mice during pregnancy and against 
vertical transmission and fetal demise [102]. Both of these constructs were used in phase I human 
clinical trials, with VRC5283 advancing to phase II clinical trials (Table 1).  
In a separate study, a consensus sequence of prM-E was generated from ZIKV strains isolated 
between the years 1952 and 2015 and optimized for expression and secretion with the addition of the 
SS of immunoglobulin [103] and cloned in a DNA vaccine vector. Following enhanced DNA delivery 
by electroporation using Inovio’s proprietary intradermal DNA delivery device, the vaccinated 
animals generated neutralizing antibodies and antigen-specific cellular immune responses that 
protected mice and NHPs from viremia and testes damage upon virus challenge [104]. This vaccine, 
GLS-5700, in phase I clinical trials, elicited ZIKV-binding antibodies in 100% individuals but only 
60% of individuals in the study had neutralizing antibodies [68]. However, the immune responses 
were found to be protective in in vitro and in vivo models of ZIKV infection. Other DNA vaccine 
candidates that have demonstrated promise in preclinical/animal studies include NS1 as the target. 
A DNA vaccine encoding a secreted form of NS1 protein was shown to protect immunocompetent 
mice from systemic ZIKV infection. Although the NS1-specific antibodies failed to protect the mice 
from the virus infection, functional NS1-specific T cell responses were critical for protection [63]. On 
the other hand, another NS1-expressing DNA vaccine in the presence of two boosters of 
immunization with soluble NS1 was shown to induce high titers of antibody that, upon passive 
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transfer, could protect immunocompromised mice against ZIKV lethal challenge [91]. Interestingly, 
these NS1-specific antibodies are long-lasting and were responsible for Fc-mediated effector 
functions for protection [91]. 
Table 1. ZIKV vaccine candidates and their status in clinical trials. 
Platform Vaccine Name Sponsor Antigen 
Status in Clinical Trials 
Phase 1      Phase 2 
DNA 
VRC5283 
NIAID/VRC 
prM-E NCT02996461 NCT03110770 
VRC5288 prM-E NCT02840487  
GLS-5700 
GeneOne Life Science, 
Inc./ Inovio 
Pharmaceuticals 
prM-E 
NCT02809443/ 
NCT02887482 
 
RNA 
mRNA-1325  
Moderna Therapeutics 
prM-E 
NCT03014089  
mRNA-1893 NCT04064905  
Live 
Attenuated 
Viral 
Vectored 
rZIKV/D4Δ30-
713 
NIAID prM-E NCT03611946  
MV-ZIKV 
Themis Bioscience GmbH 
prM-sE NCT02996890  
MV-ZIKV-
RSP 
prM-E NCT04033068  
ChAdOx1 
Zika 
University of Oxford prM-E NCT04015648  
Inactivated 
Virus 
ZPIV NIAID/WRAIR/BIDMC 
Whole 
virion 
NCT02963909 
NCT02952833 
NCT02937233 
NCT03008122 
 
PZIV (TAK-
246) 
Takeda Pharmaceuticals 
Whole 
virion 
NCT03343626  
BBV121 Bharat Biotech 
Whole 
virion 
CTRI/2017/05/ 
008539 
 
VLA1601 
Valneva Austria GmbH/ 
Emergent Biosolutions 
Whole 
virion 
NCT03425149  
BIDMC, Beth Israel Deaconess Medical Center; ChAdOx1, Chimpanzee Adenovirus Oxford 1; NIAID, 
National Institute of Allergy and Infectious Diseases; PZIV, purified Zika inactivated vaccine; VRC, 
Vaccine Research Center; WRAIR, Walter Reed Army Institute of Research; ZPIV, ZIKV purified 
inactivated vaccine. 
4.1.2. mRNA Vaccines 
Due to the inherent instability of mRNA and its ability to activate innate immune signaling 
pathways, use of modified nucleosides during in vitro transcription was shown to render mRNAs 
less immunogenic [105] and also enhanced its translational capacity [106,107]. In vitro transcribed 
mRNAs incorporating 1-methylpseudouridine in place of uridine and/or 5-methylcytidine in place 
of cytidine have now been used as vaccine candidates for infectious diseases and cancer [99]. Using 
this approach, several ZIKV RNA vaccine candidates [71,102,108,109] have been developed and 
evaluated in preclinical and human clinical trials.  
An mRNA for the prM-E region of the ZIKV H/PF/2013 was synthesized in vitro in the presence 
of the modified nucleoside, 1-methylpseudouridine and encapsulated with lipid nanoparticles 
(LNP). In immunocompetent mice and rhesus macaques, single intradermal injection of the 
nucleoside-modified mRNA-LNP induced a robust neutralizing antibody response and ZIKV-
specific cellular responses that conferred complete protection form the virus challenge [71]. In a 
similar approach, another group also developed prM-E-expressing mRNA vaccines [108] that could 
protect mice from lethal ZIKV challenge and confer sterilizing immunity. A prime-boost approach 
was found to induce very high levels of neutralizing antibody titers. In follow up studies, these 
mRNA vaccines were shown to mediate protection against ZIKV virus-induced congenital disease 
[109] and protect immunocompetent and immunocompromised mice during pregnancy [102]. These 
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latter mRNA vaccines (mRNA-1325 and mRNA-1895) are undergoing phase I clinical trials (Table 1) 
by Moderna Therapeutics, a Cambridge, MA based Biotech Company. 
4.2. Live Attenuated Vaccines  
With the development of infectious molecular clones of many wild-type and vaccine strains of 
flaviviruses, it has been possible to generate live attenuated vaccine candidates through genetic 
manipulation. At least two major strategies have been employed to develop live attenuated ZIKV 
vaccines: (i) introducing specific attenuating mutations into ZIKV genome, and (ii) generating 
chimeric flaviviruses expressing the prM-E genes of ZIKV in the genetic background of DENV, JEV, 
or YFV. Through the introduction of 10 or 20 nucleotide deletions within the 3′-untranslated region 
(UTR) of the Cambodian strain (FSS13025) ZIKV, the deletion mutant viruses were found to be highly 
attenuated, and conferred sterilizing immunity in immunocompromised mice with high titers of 
neutralizing antibodies and robust T cell responses [110]. Additionally, while the 3′-UTRΔ10 vaccine 
candidate prevented the vertical transmission of the challenge virus in pregnant mice, both 3′-
UTRΔ10 as well as 3′-UTRΔ20 vaccine candidates were shown to prevent testis damage and injury in 
male mice [111]. In NHPs, a single-dose of both vaccines induced immune response to block viremia 
while the 3′-UTRΔ20 virus elicited sterilizing immunity [111]. In addition, by eliminating 
glycosylation sites in E and/or NS1 proteins, it was also shown that the mutant viruses were 
attenuated, induced robust neutralizing antibody responses as well as T cell responses that in 
immunocompromised mice, conferred protection [112,113].  
Chimeric DENV serotype 2 and JEV-encoding prM-E proteins of ZIKV, in place of their 
corresponding proteins, have also been generated [114,115]. While the DENV-2/ZIKV chimeric 
vaccine conferred protection of immunocompromised mice [114], the JEV/ZIKV chimeric vaccine 
protected mice and NHPs from ZIKV challenge as well as from placental and fetal damage [115]. 
Perhaps the most interesting live attenuated chimeric Zika virus vaccine candidate that has entered 
phase I clinical trials is the chimeric vaccine in the genomic backbone of DENV serotype 4 that 
expresses the prM-E proteins of ZIKV. This vaccine, rZIKV/D4Δ30-713, contains a 30-nucleotide 
deletion in the 3′-UTR of the DENV genome that results in reduced replication and significant 
attenuation in NHPs and humans. One of the major challenges for an efficacious ZIKV chimeric 
vaccine using DENV or JEV as genomic backbones is the presence of pre-existing immunity against 
these flaviviruses. Since there are cross-reactive antibodies in flavivirus endemic areas, it is possible 
that these antibodies could inhibit or alter the immune responses elicited by a flavivirus-based 
chimeric ZIKV vaccine. Response to such chimeric ZIKV vaccines might be different in individuals 
with pre-existing flavivirus antibodies as compared to those without. Additionally, as discussed 
above, such pre-existing antibodies could also enhance vaccine-mediated pathogenicity, possibly via 
ADE. Furthermore, it should be borne in mind that chimeric flavivirus-based ZIKV vaccine 
candidates could potentially pose risks of exacerbated disease in flavivirus naïve population as has 
been observed with the chimeric attenuated yellow fever virus (17D) genome-based tetravalent 
DENV vaccine [116], where administration of the vaccine (Dengvaxia®) to naïve children resulted in 
more severe Dengue-related complications as compared to the unvaccinated group [117]. 
It should be noted that live attenuated ZIKV vaccines or live viral-vectored vaccines could 
present potential safety concerns for pregnant women if these vaccines breach the maternal–fetal 
barrier and cause fetal damage. These vaccines should be carefully evaluated for their safety with 
more stringent data on maternal transmission using various animal models including NHPs, even 
though there is no certainty that these preclinical data will be reproducible in humans. Therefore, 
most vaccine developers prefer the administration of inactivated or subunit vaccines without 
adjuvants, or with adjuvants that are currently approved for use in other vaccines for pregnant 
women. 
4.3. Vaccines Employing Other Recombinant Viral Vectors 
Replication-competent or -defective viral vectors expressing the prM-E genes of ZIKV have also 
been developed as vaccine candidates. These include vesicular stomatitis virus (VSV), measles virus 
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(MV), vaccinia virus, and adenovirus (Ad). An attenuated version of a recombinant VSV expressing 
the prM-E of ZIKV elicited both neutralizing antibody responses and T cell responses that protected 
challenged newborn mice born to vaccinated female mice [118]. A live attenuated measles virus 
vector expressing prM and soluble E (MV-Zika-sE) was shown to protect mice from ZIKV challenge 
through the development of E-specific neutralizing antibodies and cellular immune responses [119]. 
The immunization of NHPs also resulted in Zika-virus-specific neutralizing antibody responses in 
all vaccinated animals. This vaccine and another similarly developed MV vaccine (MV-ZIKV-RSP) 
are in human phase I clinical trials (Table 1). A vaccinia-based single vector construct expressing prM-
E of ZIKV and the structural proteins of chikungunya virus (C-E3-E2-6K-E1) induced neutralizing 
antibody responses to both viruses in immunocompetent and immunocompromised mice and 
blocked ZIKV viremia and disease [120]. Additionally, this vaccine candidate also blocked the vertical 
transmission of ZIKV in immunocompromised female mice and testes damage in male mice [120]. 
Several adenovirus vectors expressing prM-E and/or E alone have been developed and shown 
promise as potential vaccines for ZIKV [70,101,121–125]. These vectors encode prM-E or E alone and 
have been shown to induce neutralizing antibodies and cellular immune responses that confer 
protection in mice and NHPs. The protection in NHPs has been found to last for at least one year 
[121]. Interestingly, one adenovirus-based vector only induced a T cell-biased protective response 
without neutralizing antibody response [124]. A vaccine candidate based on chimpanzee adenovirus 
ChAdOx1 encoding prM-E (without the transmembrane domain) of ZIKV is currently in phase I 
clinical trials (Table 1).  
4.4. Virus-Like Particle (VLP) Vaccines and Subunit Protein Vaccines 
Virus-like particles (VLPs) containing the structural proteins of ZIKV, namely, prM-E have been 
generated in various expression systems and examined for their ability to induce neutralizing 
antibody response as well as cellular immune responses that can protect from the virus challenge. 
The DNA- and RNA-based vaccines and recombinant viral vectors described above generated VLPs 
directly in the animals for the induction of a protective immune response. However, the use of 
various expression systems to generate and purify the VLPs for administration into animals has 
advantages in that the animals respond to only the viral antigens without any other components. 
Several such vaccine candidates have been tested in preclinical studies and shown to induce 
neutralizing antibody and cellular immune responses [126–129] and protect immunocompromised 
mice against lethal virus challenge [128].  
Purified recombinant ZIKV proteins have also been developed as vaccine candidates, although 
their utility in clinical studies has lagged compared to other vaccine candidates. These subunit protein 
vaccines are considered to be potentially safe in most target populations but have limitations in that 
they are not as immunogenic as the other vaccines, due to the fact that they are likely not presented 
to the host immune system in their native conformation. However, modifications to protein 
structures, particularly through the introduction of mutations to stabilize the quaternary structures 
of the viral E protein, have resulted in vaccine candidates that, in immunized mice, induce 
neutralizing antibody responses and confer protection against ZIKV challenge [130,131] during 
pregnancy in addition to eliminating ADE [130].  
In an attempt to avoid ADE, others have developed vaccine candidates by expressing only the 
domain III (EDIII) of the E protein. E. coli expressed EDIII elicited neutralizing antibody titers in 
immunocompetent mice that could neutralize ZIKV in vitro and did not exhibit ADE [132]. In a 
separate study, a non-neutralizing epitope in EDIII was shielded by the introduction of a 
glycosylation site at residue 375. The modified EDIII protein induced significantly higher 
neutralizing antibodies in mice and fully protected pregnant mice and their fetus against lethal 
challenge [133]. When EDIII was presented on the surface through chemical crosslinking with an 
immunologically optimized VLP generated from cucumber mosaic virus with a Th cell epitope from 
tetanus toxin (CuMVtt), the resulting VLP induced neutralizing antibodies with no ADE activity 
[134]. 
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5. Immunoinformatics Approach for Peptide Vaccines 
As described above, numerous vaccine candidates for ZIKV have entered preclinical and clinical 
evaluations. The antigens for these vaccine candidates have often been comprised of the full-length 
or specific domains of the viral proteins. In recent years, the ability to predict B cell and T cell epitopes 
using a variety of bioinformatics and immunoinformatics tools [135] coupled with the availability of 
homology modeling and molecular docking methods, have added a new dimension to vaccinology: 
the peptide vaccines. The peptide vaccine approach has gained interest since a single peptide 
incorporating multiple dominant B cell and T cell epitopes from a number of viral proteins can be 
designed and used as an immunogen. These computational methods have been applied to in silico 
prediction for the development of ZIKV peptide vaccines [136–139]. Both linear and conformational 
epitopes for B and T cell responses have been predicted for the entire ZIKV proteome that could be 
incorporated in the design of peptide vaccines. However, it should be noted that these peptide 
vaccines have not been tested yet for their ability to induce a protective immune response to ZIKV 
infections. In one study [139], a multi-epitope-based-peptide vaccine immunogen was designed so 
that it contained multiple immunodominant epitopes from the ZIKV proteome. This immunogen, a 
435-amino-acid-residues-long protein, contains multiple epitopes tandemly pieced together, with 
linkers separating the epitopes and an adjuvant at the amino-terminus. It would be interesting to 
examine whether such an in silico generated immunogen would induce the predicted humoral and 
cell-mediated immune responses for protection against ZIKV. 
6. Challenges and Future Perspectives 
Over the last four years, significant efforts have been made by researchers worldwide to develop 
safe and efficacious vaccines for ZIKV. This has resulted in the development of at least 13 vaccine 
candidates under various platforms that have entered 17 different human phase I clinical trials with 
one entering phase II clinical trial. Additionally, many vaccine candidates have been tested in 
preclinical studies and have demonstrated significant promise for further development. 
Undoubtedly, this is considered a major success, although much work remains to be completed to 
bring a ZIKV vaccine to licensure and for public use. Several concerns need to be addressed before a 
successful ZIKV is deployed. 
1. Since cases of human ZIKV infections have essentially disappeared in the past two years, efficacy 
testing of ZIKV vaccine candidates in target populations is challenging. Alternatively, a 
controlled human infection model could be developed not only to test vaccine efficacy but also 
determine the correlates of protection in humans. The development of such models needs the 
participation of volunteers that require approval by appropriate regulatory bodies, which 
should take into consideration the ethical issues as well as social benefits of infecting the 
volunteers with ZIKV. Given this situation, the WHO, and the NIH (USA) concluded that ZIKV 
vaccine efficacy trials in the absence of outbreaks are not feasible, and that a robust definition of 
immunological markers predicting protection should be developed [140] before a ZIKV vaccine 
can move to licensure; 
2. A sustained source of support for the development of vaccines should be identified/maintained 
in the face of a waning epidemic. This has been a serious concern with ZIKV vaccine 
development projects. When a sudden and significant outbreak of an epidemic occurs that 
threatens public health, emergency funding from governments becomes readily available, only 
to dry out later as the epidemic wanes, leaving the vaccine development projects incomplete. 
Although the US Food and Drug Administration (FDA) has instituted incentive programs for 
developing vaccines that are not profitable for developers, a more robust partnership between 
government and private sectors should be built to address these concerns; 
3. Recent studies suggest that pre-existing flavivirus antibodies in humans may not be a major 
concern for the ADE of ZIKV; however, more detailed investigations are needed. Likewise, 
studies should also address whether administering ZIKV vaccines to naïve or flavivirus-exposed 
individuals would affect the efficacy of the vaccine; 
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4. Since ZIKV causes a variety of congenital diseases and GBS, whether a single vaccine would 
adequately protect pregnant women, women of child-bearing ages, children, and adults need to 
be determined. Several vaccine candidates have been shown to protect the placenta and the fetus 
of pregnant mice and NHPs and testis damage in males from ZIKV; whether these vaccines can 
protect pregnant women and the unborn remains to be determined. What are the correlates of 
protection in these target populations? It is likely that different types of vaccines are needed for 
different target populations, as the correlates of protection may be different for each group and 
vaccine type. This should be determined with additional studies. Answers to these critical 
questions through further preclinical studies and clinical trials would help in developing an 
effective vaccine. 
7. Summary and Conclusions 
Since the declaration of ZIKV and its associated diseases as a public health emergency, 
remarkable progress has been achieved for the development of ZIKV vaccine candidates. Many of 
these candidates have shown significant promise in various animal models and several have now 
entered human clinical phase I/II trials. However, further evaluation of these vaccine candidates in 
human clinical trials appears unlikely, due primarily to lack of funding, the high financial costs 
associated with these studies and uncertain levels of profit for the private sector companies. 
Partnerships between government institutions and private sector companies should enable further 
clinical testing and eventual licensure and manufacturing of ZIKV vaccines ready for deployment, 
should a ZIKV epidemic occur in the future. As ZIKV has caused a significant epidemic in the 
Americas and many other parts of the world recently, it is uncertain when and where the next 
epidemic will occur. The scientists, biopharmaceutical companies, public health officials, and policy 
makers must come together to prepare well for the next outbreak of ZIKV with efficacious vaccines 
and antivirals. 
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